摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-methyl-2-cyclopropyl-pentan-2-ol | 824-17-9

中文名称
——
中文别名
——
英文名称
4-methyl-2-cyclopropyl-pentan-2-ol
英文别名
(+/-)-(1-hydroxy-1.3-dimethyl-butyl)-cyclopropane;(+/-)-(1-Hydroxy-1.3-dimethyl-butyl)-cyclopropan;(+/-)-2-Cyclopropyl-4-methyl-pentan-1-ol;Isobutyl-methyl-cyclopropylcarbinole;2-Cyclopropyl-4-methyl-2-pentanol;2-Cyclopropyl-4-methylpentan-2-ol
4-methyl-2-cyclopropyl-pentan-2-ol化学式
CAS
824-17-9
化学式
C9H18O
mdl
——
分子量
142.241
InChiKey
CZSOSAOSDGZXJB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    174-175 °C(Press: 759 Torr)
  • 密度:
    0.86958 g/cm3

计算性质

  • 辛醇/水分配系数(LogP):
    2.2
  • 重原子数:
    10
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    20.2
  • 氢给体数:
    1
  • 氢受体数:
    1

反应信息

点击查看最新优质反应信息

文献信息

  • BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS
    申请人:Knopp Biosciences LLC
    公开号:US20160075663A1
    公开(公告)日:2016-03-17
    Optionally substituted benzoimidazol-1,2-yl amides, such as compounds of Formula 1 or Formula 2, can be used to treat disorders associated with a Kv7 potassium channel activator. Compositions, medicaments, and dosage forms related to the treatment are also disclosed herein.
    可选择替代的苯并咪唑-1,2-基酰胺,如式1或式2的化合物,可用于治疗与Kv7钾通道激活剂相关的疾病。本文还公开了与治疗相关的组合物、药物和剂型。
  • Julia,S. et al., Comptes Rendus Hebdomadaires des Seances de l'Academie des Sciences, 1961, vol. 253, p. 678 - 680
    作者:Julia,S. et al.
    DOI:——
    日期:——
  • Henry, Bulletin des Societes Chimiques Belges, 1931, vol. 40, p. 647,651
    作者:Henry
    DOI:——
    日期:——
  • BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE
    申请人:Hung David T.
    公开号:US20100099667A1
    公开(公告)日:2010-04-22
    This disclosure relates to new compounds that may be used to modulate a histamine receptor in an individual. Novel compounds are described, including new bridged heterocyclic [4,3-b]indole compounds. Pharmaceutical compositions are also provided. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.
  • US8338447B2
    申请人:——
    公开号:US8338447B2
    公开(公告)日:2012-12-25
查看更多